Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...1112131415161718192021...136137»
  • ||||||||||  cyclosporin A microemulsion / Generic mfg.
    Review, Journal:  Good's Syndrome With Pure Red Cell Aplasia and Subclinical Myasthenia Gravis: A Case Report and Review of Literature. (Pubmed Central) -  Jun 5, 2024   
    A review of the literature on simultaneous Good's syndrome with PRCA also suggested the efficacy of CsA on PRCA but not hypoglobulinemia, suggesting the distinct underlying mechanisms between these two paraneoplastic symptoms with thymoma. Future research is needed to understand the mechanism underlying this rare pathologic condition and to generate appropriate treatment.
  • ||||||||||  Trial completion, Enrollment change, Real-world evidence, Real-world:  The Impact of Myasthenia Gravis in the Real World (clinicaltrials.gov) -  Jun 3, 2024   
    P=N/A,  N=2847, Completed, 
    No abstract available Recruiting --> Completed | N=2000 --> 2847
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report. (Pubmed Central) -  Jun 2, 2024   
    While the incidence of "de-novo" diseases secondary to immune checkpoint inhibitors might be increasing, guidelines regarding best treatment options do not yet exist, leaving many providers at a loss when faced with making clinical decisions surrounding patients with De novo myasthenia gravis. Thus, our goal is to underscore the importance of early recognition of this disease, and emphasize the need for a standard of care as immune checkpoint inhibitors usage becomes more prevalent.
  • ||||||||||  Surgical management of locally advanced thymomas (PS-28; Poster board no. 1) -  May 31, 2024 - Abstract #ERS2024ERS_3368;    
    Surgical management of LAT requires a multidisciplinary approach. Minimally invasive approaches are effective in achieving favorable outcomes and good survival rates
  • ||||||||||  prednisone / Generic mfg., azathioprine / Generic mfg.
    Challenges in Robotic thymectomy: stage IVa Myasthenia Gravis pediatric patient (PS-18; Poster board no. 14) -  May 31, 2024 - Abstract #ERS2024ERS_2320;    
    A MDT approach is imperative for optimal disease management and the integration of medical care and optimal surgical timing are essential steps in achieving favorable outcomes. However, these cases necessitate the resources and expertise available at large, specialized centers.
  • ||||||||||  Journal:  Congenital myasthenic syndromes. (Pubmed Central) -  May 30, 2024   
    However, these cases necessitate the resources and expertise available at large, specialized centers. No abstract available
  • ||||||||||  Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
    Journal:  Amifampridine overdose leading to refractory status epilepticus. (Pubmed Central) -  May 30, 2024   
    Aminopyridine overdoses are commonly thought to carry low morbidity and mortality; however, our patient had both a cardiac arrest and refractory status epilepticus. Ultimately, this case suggests that patients who overdose on 3,4-Aminopyridine could become critically ill and their presentation may be far more severe than that of other medications of the same class.
  • ||||||||||  CORRELATION BETWEEN NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNOLOGICAL MARKERS () -  May 29, 2024 - Abstract #EULAR2024EULAR_3225;    
    Various neuropsychiatric manifestations in SLE were found to be correlated with specific autoantibodies. Independent risk factors for NPSLE included aPT IgM antibodies, age, and elevated serum creatinine, while the absence of anti-SSB antibodies and low complement C3 levels were associated with reduced risk.
  • ||||||||||  Journal:  Perioperative cardiac risks in myasthenia gravis. (Pubmed Central) -  May 29, 2024   
    Increased incidence of atrial fibrillation, ventricular and supraventricular extra systoles, and prolonged QTc have also been reported in patients with MG. Clinicians should consider the evaluation of autonomic dysfunction and risk of cardiovascular disease in patients with MG.
  • ||||||||||  Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
    Clinical, Journal, Real-world evidence, Real-world:  Real-World experience with efgartigimod in patients with myasthenia gravis. (Pubmed Central) -  May 29, 2024   
    We found that efgartigimod is clinically effective, may be used as a steroid sparing agent and is generally safe for gMG patients. We recommend a personalized preventive treatment approach until clinical stabilization, followed by discontinuation and periodic evaluations.
  • ||||||||||  Journal:  Quantification of saccadic fatigability and diagnostic efficacy for myasthenia gravis. (Pubmed Central) -  May 26, 2024   
    The utilization of VOG for repetitive saccadic testing in the diagnosis of MG has demonstrated considerable diagnostic precision. This methodology affords significant accuracy in evaluating ocular muscle fatigue in MG patients, providing class III evidence supportive of its clinical application.
  • ||||||||||  Review, Journal:  Does Surgical Removal of the Thymus Have Deleterious Consequences? (Pubmed Central) -  May 23, 2024   
    We conclude that for patients with acetylcholine receptor antibody-positive MG and those diagnosed with thymoma, the removal of the thymus offers prominent benefits that well outweigh the potential risks. However, incidental removal of thymic tissue during other thoracic surgeries should be minimized whenever feasible.
  • ||||||||||  Journal:  Impact of therapeutic plasma exchange on intact protein S, apolipoproteins, and thrombin generation. (Pubmed Central) -  May 20, 2024   
    The incidence of MG decreased during COVID-19 pandemic, and the severity of MG was not affected by COVID-19. After the five settings of TPE using S/D-plasma in vivo, which associated with heparinization and reduced coagulation factor activities, our observations of declining natural anticoagulant intact PS and apolipoproteins refer to rebalance of the hemostatic and lipid profiles.